Guide to Preventing Readmissions Among Racially & Ethnically Diverse Medicare Beneficiaries
As part of the CMS Equity Plan for Improving Quality in Medicare, CMS OMH, in collaboration with the Disparities Solutions Center at Massachusetts General Hospital and NORC at the University of Chicago, produced a Guide to Preventing Readmissions among Racially and Ethnically Diverse Medicare Beneficiaries
. This Guide is designed to equip hospital leaders, as well as QIN-QIOs and HENs, with guidance for addressing avoidable readmissions in this population. The Guide provides a set of action-oriented recommendations, as well as case examples of initiatives that may be applied to reduce readmissions in diverse populations.
Download the Guide
A Practitioner's Guide for Advancing Health Equity: Community Strategies for Preventing Chronic Disease
The Centers for Disease Control has released a new Health Guide resource. The opening section discusses practices and principles for incorporating health equity goals into organizations’ activities. While the focus of the document is public health and community organizations, it provides great ideas and examples that are useful across settings.
Racial and Ethnic Disparities in Access to and Utilization of Care among Insured Adults
The Kaiser Family Foundation has a new issue brief out looking at the extent to which people of color may continue to experience disparities in access to and utilization of care even after ACA implementation. The brief examines differences in access to and utilization of care for Black and Hispanic adults compared to White adults among those who are uninsured, enrolled in Medicaid, and privately insured, using data from the 2014 Kaiser Survey of Low-Income Americans.
Equity of Care - Culturally Competent Care
Sr. Carol Keehan, DC
Reprinted with permission of Health Administration Press from Journal of Healthcare Management
, vol. 58, no. 4, pp. 250-252. Copyright 2013.
Lack of Diversity in Medical Research Is Bad for Your Health (National Journal
Low participation of minority populations in clinical trials can lead to development of medicines that are dangerous for the people using them.